These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11073849)

  • 21. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.
    Jonkers IJ; Smelt AH; Ledeboer M; Hollum ME; Biemond I; Kuipers F; Stellaard F; Boverhof R; Meinders AE; Lamers CH; Masclee AA
    Gut; 2003 Jan; 52(1):109-15. PubMed ID: 12477770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F; Mannucci L; Mussoni L; Gianfranceschi G; Maderna P; Werba P; Franceschini G; Sirtori CR; Tremoli E
    Eur J Clin Pharmacol; 1992; 43(3):219-23. PubMed ID: 1425883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative modification of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits in vivo.
    Liu BW; Jiang Y; Fu MD; Liu Y; Fan P
    Mol Cell Biochem; 2000 Apr; 207(1-2):131-5. PubMed ID: 10888238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
    Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy.
    de Man FH; Nieuwland R; van der Laarse A; Romijn F; Smelt AH; Gevers Leuven JA; Sturk A
    Atherosclerosis; 2000 Oct; 152(2):407-14. PubMed ID: 10998469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.
    Okumura T; Fujioka Y; Morimoto S; Tsuboi S; Masai M; Tsujino T; Ohyanagi M; Iwasaki T
    Am J Med Sci; 2002 Nov; 324(5):247-53. PubMed ID: 12449445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease.
    Hughes TA; Elam MB; Applegate WB; Bond MG; Hughes SM; Wang X; Tolley EA; Bittle JB; Stentz FB; Kang ES
    Metabolism; 1995 Aug; 44(8):1082-98. PubMed ID: 7637651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
    Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
    Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Composition and distribution of lipid and apolipoprotein in plasma lipoproteins of endogenous hypertriglyceridemia].
    Zhang L; Liu B
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):117-21. PubMed ID: 1452137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase.
    Chung BH; Segrest JP; Franklin F
    Atherosclerosis; 1998 Dec; 141(2):209-25. PubMed ID: 9862170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation.
    Whitman SC; Miller DB; Wolfe BM; Hegele RA; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1707-15. PubMed ID: 9327767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers.
    Fahlbusch SA; Tsikas D; Mehls C; Gutzki FM; Böger RH; Frölich JC; Stichtenoth DO
    Eur J Clin Pharmacol; 2004 Apr; 60(2):83-8. PubMed ID: 15004731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
    Mohrschladt MF; Weverling-Rijnsburger AW; de Man FH; Stoeken DJ; Sturk A; Smelt AH; Westendorp RG
    Atherosclerosis; 2000 Feb; 148(2):413-9. PubMed ID: 10657578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE; Noll G; Hannak M; Lüscher TF
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.